We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biomarker Predicts Prognosis in Acute Myeloid Leukemia Patients

By LabMedica International staff writers
Posted on 13 Jan 2020
Acute myeloid leukemia (AML) is the most prevalent adult acute leukemia, which is characterized by abnormal proliferation and the accumulation of immature myeloid precursor cells in the bone marrow, peripheral blood, and even some tissues, contributing to the destruction of the hematopoietic system.

It is essential to discover potential biomarkers which could predict prognosis and guide AML management effectively in AML patients. More...
A recent study aimed to investigate the correlation of protein phosphatase Mg2+/Mn2+ dependent 1D (PPM1D) with the risk stratification, treatment response, and survival profile in AML patients.

Hematologists at the Second People's Hospital of Yunnan Province (Kunming, China) enrolled 221 de novo AML patients and 50 healthy donors between January 2016 and June 2019. Bone marrow samples of AML patients were collected before initiation of treatment, and bone marrow samples of healthy donors were acquired when examining their eligibility for bone marrow transplantation. After bone marrow samples collection, the bone marrow mononuclear cells (BMMCs) were separated by density gradient centrifugation. Then, the expression of PPM1D mRNA in mononuclear cells was detected by reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR), and the expression of PPM1D protein in mononuclear cells was measured by Western blot. Complete remission (CR) was assessed after induction treatment, and event‐free survival (EFS) and overall survival (OS) were calculated in AML patients.

The team reported that PPM1D mRNA/protein relative expressions were increased in AML patients compared with healthy donors, and receiver operating characteristic curve presented that PPM1D mRNA (AUC: 0.728)/protein (AUC: 0.782) relative expressions could differentiate AML patients from healthy donors. In AML patients, PPM1D mRNA/protein high relative expressions were correlated with poor‐risk stratification. As for its association with prognosis, PPM1D mRNA/protein relative expressions were elevated in CR patients compared with non‐CR patients. Patients with PPM1D mRNA/protein high relative expressions exhibited reduced EFS and OS compared with those with low expressions.

The authors concluded that PPM1D high expression correlates with poor‐risk stratification and might serve as a potential biomarker for worse prognosis in AML patients, suggesting its potential to guide AML management. The study was published on January 3, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Second People's Hospital of Yunnan Province


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.